news
Associations of AML MRD levels with posttransplant clinical outcomes
Patients with no detectable FLT3 mutations had the best outcomes after an allogenic hematopoietic cell transplant.
List view / Grid view
acute myeloid leukaemia (AML)
news
Targeting RAS to overcome FLT3 AML drug resistance
It was discovered that targeting RAS proteins prevent cancer cells from using different signalling pathways to escape cell death.
news
New strategies to overcome CAR T-cell resistance in AML cells
Pharmacological concomitant therapies or further genetic improvement of CAR T-cells can increase their effectiveness against TP53-mutant AML cells.
news
Improved CAR T-cell immunotherapy for acute myeloid leukaemia
Researchers have created dual-targeted CARs, which performed better than single-targeted CARs in both in vivo and in vitro experiments.
news
Reducing drug resistance in acute myeloid leukaemia patients
Researchers conducted a proteogenomic characterisation and found that drug exposure changes drug sensitivity.
news
PLK4 inhibition: a new therapeutic for AML
PLK4 inhibition could be a novel therapeutic for an acute myeloid leukaemia subtype carrying the TP53 mutation.
news
RBM5: potential drug target for acute myeloid leukaemia
RBM5 removal from cells meant that HOXA9 mRNA levels were greatly reduced, which could lead to therapies targeting HOXA9-driven leukaemia.
news
How gene regulatory networks maintain FLT3-ITD mutated AML
Using shRNA screening enabled researchers to investigate the roles of individual specific factors in maintaining the network found in AML.
news
An altered protein can combat the growth of leukaemia cells
Discovery about the NPM1c variant could lead to new drugs targeting the cell growth of acute myeloid leukaemia.
news
Noncoding RNA could be a new target for acute myeloid leukaemia
Discovery about the DNA of leukaemia cells suggests promising target for gene therapy in paediatric oncology.
news
Novel tool helps differentiate between cancerous and healthy cells for AML
Spanish scientists have developed a new method to identify between cancerous and healthy cells for cases of acute myeloid leukaemia (AML).
news
Recombining drugs helps restore gene’s ability to signal for death of leukaemia cells
US researchers find combination of chloroquine and venetoclax promotes cancer cell death in mouse models with acute myeloid leukaemia (AML).
article
The advantages of gamma-delta T-cell therapy
Here, Dr Michael Leek describes the benefits of gamma-delta T cells for cancer therapy, exploring why they present a potential alternative to other immuno-oncology platforms.
news
Researchers discover new compounds to potentially combat leukaemia
Researchers from the US have identified several new small molecules that can induce mitophagy in leukaemia cells.
news
New research could bring life-saving benefits of CAR T therapy to AML patients
Researchers have developed a novel method for enhancing CAR T therapy through a drug combination and cellular engineering that improves the strength and durability of the tumour-killing effect of a CAR T directed against AML.